Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors ; volume:11 ; number:1 ; day:24 ; month:2 ; year:2009 ; pages:1-14 ; date:6.2009
Breast cancer research ; 11, Heft 1 (24.2.2009), 1-14, 6.2009
- Urheber
-
Frogne, Thomas
- Beteiligte Personen und Organisationen
-
Laenkholm, Anne-Vibeke
Lyng, Maria B.
Henriksen, Katrine Lütken
Lykkesfeldt, Anne E.
SpringerLink (Online service)
- DOI
-
10.1186/bcr2230
- URN
-
urn:nbn:de:1111-201603244841
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Frogne, Thomas
- Laenkholm, Anne-Vibeke
- Lyng, Maria B.
- Henriksen, Katrine Lütken
- Lykkesfeldt, Anne E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mod.Nr. 1220 (1221, 1222)
Mod.Nr. 1220 (1221, 1222)
Mod.Nr. 1220 (1221, 1222)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
122/62 (Allgemein), 122.1/62, 122.2/62
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Mod.Nr. 1220 (1221, 1222)
Mod.Nr. 1220 (1221, 1222)
Mod.Nr. 1220 (1221, 1222)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
122/62 (Allgemein), 122.1/62, 122.2/62
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Mod.Nr. 1220 (1221, 1222)
Mod.Nr. 1220 (1221, 1222)
Mod.Nr. 1220 (1221, 1222)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
122/62 (Allgemein), 122.1/62, 122.2/62
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2